Syngeneic fibroblasts transfected with a plasmid encoding interleukin-4 as non-viral vectors for anti-inflammatory gene therapy in collagen-induced arthritis

Journal of Gene Medicine

Volumn 4, Issue 3, 2002, Pages 300-307

  Bessis, Natacha ^a   Cottard, Virginie ^a   Saidenberg Kermanach, Nathalie ^a   Lemeiter, Delphine ^a   Fournier, Catherine ^b   Boissier, Marie Christophe ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b INSERM   (France)

Author keywords

Cellular vectors; Cytokines; Experimental models; Gene therapy; Inflammation; Rheumatoid arthritis

Indexed keywords

COLLAGEN TYPE 2; COMPLEMENTARY DNA; INTERLEUKIN 4; PLASMID VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CELL IMMORTALIZATION; CHO CELL; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; GENETIC TRANSFECTION; HISTOLOGY; IMMUNIZATION; JOINT DESTRUCTION; MALE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; ANIMAL; CELL DIVISION; CELL LINE; CYTOLOGY; DBA MOUSE; GENE THERAPY; GENE VECTOR; GENETICS; HAMSTER; IMMUNOLOGY; METABOLISM; PLASMID; T LYMPHOCYTE;

CRICETINAE; CRICETULUS GRISEUS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CELL DIVISION; CELL LINE, TRANSFORMED; CHO CELLS; CRICETINAE; FIBROBLASTS; GENE THERAPY; GENETIC VECTORS; INTERLEUKIN-4; MALE; MICE; MICE, INBRED DBA; PLASMIDS; T-LYMPHOCYTES;

EID: 0036579839     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.275     Document Type: Article

References (50)

1. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor-α in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151-160.
2. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-1939.
3. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-259.
4. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980; 283: 666-668.
5. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977; 146: 857-868.
6. Cathcart ES, Hayes KC, Gonnerman WA, Lazzari AA, Franzblau C. Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen. Lab Invest 1986; 54: 26-31.
7. Boissier MC, Feng XZ, Carlioz A, Roudier R, Fournier C. Experimental autoimmune arthritis in mice. I. Homologous type II collagen is responsible for self-perpetuating chronic polyarthritis. Ann Rheum Dis 1987; 46: 691-700.
8. Mauri C, Williams RO, Walmsley M, Feldmann M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol 1996; 26: 1511-1518.
9. Doncarli A, Stasiuk LM, Fournier C, Abehsira-Amar O. Conversion in vivo from an early dominant Th0/Th1 response to a Th2 phenotype during the development of collagen-induced arthritis. Eur J Immunol 1997; 27: 1451-1458.
10. Evans CH, Ghivizzani SC, Herndon JH, et al. Clinical trials in the gene therapy of arthritis. Clin Orthop 2000; 379 Suppl.: S300.
11. Bandara G, Mueller GM, Galea-Lauri J, et al. Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci U S A 1993; 90: 10764-10768.
12. Makarov SS, Olsen JC, Johnston WN, et al. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci U S A 1996; 93: 402-406.
13. Kim SH, Evans CH, Kim S, Oligino T, Ghivizzani SC, Robbins PD. Gene therapy for established routine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4. Arthritis Res 2000; 2: 293-302.
14. Boyle DL, Nguyen KH, Zhuang S, et al. Intra-articular IL-4 gene therapy in arthritis: anti-inflammatory effect and enhanced Th2 activity. Gene Ther 1999; 6: 1911-1918.
15. Bessis N, Boissier MC, Ferrara P, Blankenstein T, Fradelizi D, Fournier C. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur J Immunol 1996; 26: 2399-2403.
16. Bessis N, Chiocchia G, Kollias G, et al. Modulation of proinflammatory cytokine production in tumour necrosis factor-alpha (TNF-alpha)-transgenic mice by treatment with cells engineered to secrete IL-4, IL-10 or IL-13. Clin Exp Immunol 1998; 111: 391-396.
17. Fellowes R, Etheridge CJ, Coade S, et al. Amelioration of established collagen-induced arthritis by systemic IL-10 gene delivery. Gene Ther 2000; 7: 967-977.
18. Whalen JD, Lechman EL, Carlos CA, et al. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol 1999; 162: 3625-3632.
19. Apparailly F, Verwaerde C, Jacquet C, Auriault C, Sany J, Jorgensen C. Adenovirus mediated transfer of viral IL-10 gene inhibits collagen-induced arthritis. J Immunol 1998; 160: 5213-5220.
20. Rabinovich GA, Daly G, Dreja H, et al. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med 1999; 190: 385-398.
21. Bessis N, Guery L, Mantovani A, et al. The type II decoy receptor of IL-1 inhibits routine collagen-induced arthritis. Eur J Immunol 2000; 30: 867-875.
22. Evans CH, Ghivizzani SC, Kang R, et al. Gene therapy for rheumatic diseases. Arthritis Rheum 1999; 42: 1-16.
23. Cottard V, Mulleman D, Bouille P, Mezzina M, Boissier MC, Bessis N. Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis. Gene Ther 2000; 7: 1930-1939.
24. Bessis N, Honiger J, Damotte D, et al. Encapsulation in hollow fibres of xenogeneic cells engineered to secrete IL-4 or IL-13 ameliorates murine collagen-induced arthritis (CIA). Clin Exp Immunol 1999; 117: 376-382.
25. Triantaphyllopoulos KA, Williams RO, Tailor H, Chernajovsky Y. Amelioration of collagen-induced arthritis and suppression of interferon-γ, interleukin-12, and tumor necrosis factor α production by interferon-β gene therapy. Arthritis Rheum 1999; 42: 90-99.
26. Platzer C, Richter G, Uberla K, Hock H, Diamenstein T, Blankenstein T. Interleukin-4-mediated tumor suppression in nude mice involves interferon-gamma. Eur J Immunol 1992; 22: 1729-1733.
27. Boissier MC, Chiocchia G, Ronzière MC, Herbage D, Fournier C. Arthritogenicity of minor cartilage collagens (type IX and XI) in mice. Arthritis Rheum 1990; 33: 1-8.
28. Manoury-Schwartz B, Chiocchia G, Bessis N, et al. High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol 1997; 158: 5501-5506.
29. Horsfall AC, Butler DM, Marinova L, et al. Suppression of collagen-induced arthritis by continuous administration of IL-4. J Immunol 1997; 159: 5687-5696.
30. Morita Y, Yang J, Gupta R, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001; 107: 1275-1284.
31. Boissier MC, Carlioz A, Fournier C. Experimental autoimmune arthritis in mice. II. Early events in the elicitation of the autoimmune phenomenon induced by homologous type II collagen. Clin Immunol Immunopathol 1988; 48: 225-237.
32. Lubberts E, Joosten LA, van Den Bersselaar L, et al. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. J Immunol 1999; 163: 4546-4556.
33. Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001; 199: 3499-3505.
34. Woods JM, Katschke KJ, Volin MV, et al. IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J Immunol 2001; 166: 1214-1222.
35. Walmsley M, Katsikis PD, Abney E, et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996; 39: 495-503.
36. Joosten LA, Lubberts E, Durez P, et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997; 40: 249-260.
37. Quattrocchi E, Dallman MJ, Dhillon AP, Quaglia A, Bagnato G, Feldmann M. Murine IL-10 gene transfer inhibits established collagen-induced arthritis and reduces adenovirus-mediated inflammatory responses in mouse liver. J Immunol 2001; 166: 5970-5978.
38. Doncarli A, Chiocchia G, Stasiuk LM, et al. A recurrent valpha17/vbeta10 TCR-expressing T cell clone is involved in the pathogenicity of collagen-induced arthritis in DBA/1 mice. Eur J Immunol 1999; 29: 3636-3642.
39. Corthay A, Johansson A, Vestberg M, Holmdahl R. Collagen-induced arthritis development requires alpha beta T cells but not gamma delta T cells: studies with T-cell-deficient (TCR mutant) mice. Int Immunol 1999; 11: 1065-1073.
40. Bakker AC, Joosten LA, Arntz OJ, et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997; 40: 893-900.
41. Chernajovsky Y, Adams G, Triantaphyllopoulos K, Ledda MF, Podhajcer OL. Pathogenic lymphoid cells engineered to express TGFbeta1 ameliorate disease in a collagen-induced arthritis model. Gene Ther 1997; 4: 553-559.
42. Chernajowky Y, Adams G, Podhajcer O, Mueller G, Robbins PD, Feldman M. Inhibition of transfer of collagen-induced arthritis into SCID mice by gene transfer of spleen cells with retrovirus expressing soluble human tumor necrosis factor receptor. Gene Ther 1995; 2: 731-735.
43. Bandara G, Robbins PD, Georgescu HI, Mueller GM, Glorioso JC, Evans CH. Gene transfer to synoviocytes: prospects for gene treatment for arthritis. DNA Cell Biol 1992; 11: 227-231.
44. Roessler BJ, Allen ED, Wilson JM, Hartman JW, Davidson BL. Adenoviral-mediated gene transfer to rabbit synovium in vivo. J Clin Invest 1993; 92: 1085-1092.
45. Evans C, Goins WF, Schmidt MC, et al. Progress in development of herpes simplex virus gene vectors for treatment of rheumatoid arthritis. Adv Drug Del Rev 1997; 27: 41-57.
46. Pan RY, Chen SL, Liu DW, Peng HJ, Tsao YP. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum 2000; 43: 289-297.
47. Miyata M, Sasajima T, Sato H, et al. Suppression of collagen-induced arthritis in mice utilizing plasmid DNA encoding interleukin-10. J Rheumatol 2000; 27: 1601-1605.
48. Song XY, Gu M, Jin WW, Klinman DM, Wahl SM. Plasmid DNA encoding transforming growth factor-beta1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model. J Clin Invest 1998; 101: 2615-2621.
49. Ivanyl D. Antigenic phenotype of NIH3T3 cell line. J Natl Cancer Inst 1987; 79: 149-153.
50. Ghivizzani SC. Gene therapy approaches for treating rheumatoid arthritis. Clin Orthop Rel Res 2000; 379 Suppl.: S288-S299.